Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance to tyrosine kinase inhibitors: calling on extra forces.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy - 1 Jun 2005

Cools Jan, Maertens Chantal, Marynen Peter

Abstract excerpt

Over the past 5 years, small molecule tyrosine kinase inhibitors have been successfully introduced as new cancer therapeutics. The pioneering work with the ABL inhibitor imatinib (Glivec, Gleevec) was rapidly extended to other types of leukemias as well as solid tumors, which stimulated the development of a variety of new tyrosine kinase inhibitors. Unfortunately, oncogenic tyrosine kinases seem to have little...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Drug Resistance
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Intracellular Signaling Peptides and Proteins

Share to Piperazines

Share to Protein-Tyrosine Kinases

Share to Pyrimidines

Source

Identifiers

PMID: 15869901
DOI: 10.1016/j.drup.2005.04.005

Genes

EGFR
FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance to tyrosine kinase inhibitors: calling on extra forces.PMID 15869901Read ↗

Mechanisms of clinical resistance to small molecule tyrosine kinase inhibitors targeting oncogenic tyrosine kinases.Semantic proximity Read ↗

Strategies to overcome resistance to targeted protein kinase inhibitors in the treatment of cancer.Semantic proximity Read ↗

Mechanisms of drug resistance in kinasesSemantic proximity Read ↗

Mechanisms of acquired resistance to tyrosine kinase inhibitorsSemantic proximity Read ↗

Molecular Mechanisms of Resistance to Tyrosine Kinase InhibitorsSemantic proximity Read ↗

Treating imatinib-resistant leukemia: the next generation targeted therapies.Semantic proximity Read ↗

Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs.Semantic proximity Read ↗

Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic StrategiesSemantic proximity Read ↗

Targeting oncogene dependence and resistance.Semantic proximity Read ↗

Emerging strategies to overcome resistance to third-generation EGFR inhibitors.Semantic proximity Read ↗

Mechanisms of Resistance to Targeted Therapies in Chronic Myeloid Leukemia.Semantic proximity Read ↗

Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.